SCHEMBL9296

SCHEMBL9296

COC(=O)/C=C/c1cnc2ccc(-c3ccccc3C)cc2c1

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 1/20 0.67
KMT2A Q03164 1/20 0.67
SMN1; SMN2 Q16637 1/20 0.67
CCNC P24863 2/20 0.50
CDK8 P49336 2/20 0.50
RAB9A P51151 1/20 0.46
LCK P06239 1/20 0.44
KDR P35968 1/20 0.44
JAK3 P52333 1/20 0.44
MAPK14 Q16539 1/20 0.44
BACE1 P56817 5/20 0.43
CTSD P07339 2/20 0.43
IP6K1 Q92551 1/20 0.43
IP6K3 Q96PC2 1/20 0.43
IP6K2 Q9UHH9 1/20 0.43
ABL1 P00519 2/20 0.42
P2RY12 Q9H244 1/20 0.41
LTB4R Q15722 1/20 0.40
ALDH1A1 P00352 2/20 0.40
CYP1A2 P05177 2/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9297 1.00 KDM4E (0.67) KDM4EKMT2ASMN1; SMN2CCNCCDK8
SCHEMBL14328057 0.81 KDM4E (0.71) KDM4EKMT2ASMN1; SMN2RAB9ALCK
SCHEMBL6070374 0.81 KDM4E (1.00) KDM4EKMT2ASMN1; SMN2CCNCCDK8
SCHEMBL6070375 0.81 KDM4E (1.00) KDM4EKMT2ASMN1; SMN2CCNCCDK8
SCHEMBL8477 0.79 LCK (0.44) KDM4EKMT2ASMN1; SMN2CCNCCDK8
SCHEMBL9715 0.79 LCK (0.44) KDM4EKMT2ASMN1; SMN2CCNCCDK8
SCHEMBL9751 0.77 KDM4E (0.70) KDM4EKMT2ASMN1; SMN2RAB9ALCK
SCHEMBL9752 0.77 KDM4E (0.70) KDM4EKMT2ASMN1; SMN2RAB9ALCK
SCHEMBL8879272 0.73 KMT2A (0.57) KDM4EKMT2ASMN1; SMN2RAB9AIP6K1
SCHEMBL8879268 0.73 KMT2A (0.57) KDM4EKMT2ASMN1; SMN2RAB9AIP6K1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9296698-B2 Amino heteroaryl compounds as beta-secretase modulators and methods of use AMGEN INC. (US) 2016-03-29 US disclosed
US-20120329830-A1 Amino Heteroaryl Compounds as Beta-Secretase Modulators and Methods of Use AMGEN INC. (US) 2012-12-27 US disclosed
EP-2504315-A1 AMINO HETEROARYL COMPOUNDS AS BETA-SECRETASE MODULATORS AND METHODS OF USE Amgen Inc. (US) 2012-10-03 EP disclosed
WO-2011063233-A1 AMINO HETEROARYL COMPOUNDS AS BETA-SECRETASE MODULATORS AND METHODS OF USE AMGEN INC. (US) 2011-05-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120329830-A1 Amino Heteroaryl Compounds as Beta-Secretase Modulators and Methods of Use BACE1, BACE2, APP KDM4E 1816/4885KMT2A 1441/4885SMN1; SMN2 3569/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.